Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Ajanta Pharma is a specialty pharmaceutical formulation company focused on Branded Generics across India, Asia and Africa, complemented by a selective US generics business and institutional antimalarial supplies; it develops, manufactures and markets finished dosage formulations from seven manufacturing facilities with an advanced R&D centre and a large front-end salesforce in emerging markets.
The business mix is heavily skewed to Branded Generics (71% of 9M FY2026 sales of Rs. 3,995 crore), with India (31%), Asia (23%) and Africa (17%) the primary markets; Ajanta emphasizes chronic therapies, claims ~50% of products are first-to-market, manages 500+ brands and deploys nearly 6,000 medical representatives globally.
Financially Ajanta delivered resilient growth with 9M FY2026 consolidated revenue of Rs. 4,031 crore (16% year-on-year), adjusted EBITDA margin around 28% and net profit margin near 20%; US generics accelerated strongly with a 46% year-on-year rise in 9M revenues, driving much of the recent uplift in consolidated performance.
The company’s R&D and manufacturing capabilities are key advantages: over 850 scientists, sustained R&D spend of about 5% of revenue, 50 active ANDAs with 19 pending approvals, and seven plants including two USFDA-approved facilities; strategic priorities emphasise new product launches, market share gains, country expansion, expense optimisation and digitalisation.
Near-term headwinds include lower institutional antimalarial procurement in Africa and elevated receivable days (114 days in 9M FY2026) which reduced cash conversion to 36% for the period; management continues high cash payout history while balancing investment in launches and selective US filings to sustain growth.
Pharmaceuticals & Biotechnology
Pharmaceuticals
38,390 Cr
Low Risk
36.4
33.9
2.4
8.5
3,314.80
2,335.00
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Ajanta Pharma Ltd (AJANTPHARM) is currently trading at 3,142.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Ajanta Pharma is a specialty pharmaceutical formulation company focused on Branded Generics across India, Asia and Africa, complemented by a selective US generics business and institutional antimalarial supplies; it develops, manufactures and markets finished dosage formulations from seven manufacturing facilities with an advanced R&D centre and a large front-end salesforce in emerging markets. The business mix is heavily skewed to Branded Generics (71% of 9M FY2026 sales of Rs. 3,995 crore), with India (31%), Asia (23%) and Africa (17%) the primary markets; Ajanta emphasizes chronic therapies, claims ~50% of products are first-to-market, manages 500+ brands and deploys nearly 6,000 medical representatives globally. Financially Ajanta delivered resilient growth with 9M FY2026 consolidated revenue of Rs. 4,031 crore (16% year-on-year), adjusted EBITDA margin around 28% and net profit margin near 20%; US generics accelerated strongly with a 46% year-on-year rise in 9M revenues, driving much of the recent uplift in consolidated performance. The company’s R&D and manufacturing capabilities are key advantages: over 850 scientists, sustained R&D spend of about 5% of revenue, 50 active ANDAs with 19 pending approvals, and seven plants including two USFDA-approved facilities; strategic priorities emphasise new product launches, market share gains, country expansion, expense optimisation and digitalisation. Near-term headwinds include lower institutional antimalarial procurement in Africa and elevated receivable days (114 days in 9M FY2026) which reduced cash conversion to 36% for the period; management continues high cash payout history while balancing investment in launches and selective US filings to sustain growth.
Over the past 52 weeks, Ajanta Pharma Ltd has traded between a low of ₹2,335.00 and a high of ₹3,314.80. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Ajanta Pharma Ltd has a market capitalization of approximately 38,390.22. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Ajanta Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 36.35 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 38,390.22 Cr, Ajanta Pharma Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Ajanta Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Ajanta Pharma Ltd is 36.35. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Ravi Agrawal Trust, a promoter-group entity linked to Ajanta Pharma’s promoters, sold the shares.
Ajanta Pharma saw a promoter entity sell 34.5 lakh shares (2.8%) via a ₹1,024 crore block deal, and it also announced a semaglutide marketing agreement with Biocon.
Q2 FY26 revenue from operations was ₹1,354 crore, and consolidated net profit was ₹260 crore, compared with ₹1,187 crore revenue and ₹216 crore profit a year earlier.
Ajanta Pharma reported consolidated PAT of ₹225 crore in Q4 FY25, up 11% year-on-year from ₹203 crore.
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Bearish
5
Neutral
5
Bullish
4
Bearish
5
Neutral
5
Bullish
36
Bearish
0
Neutral
0
Bullish
32
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1621.60 | 41,462 Cr | 36.33 | 5.14 | 0.37 | 14.15 | 18.58 | 9.63 | ||
3142.70 | 38,390 Cr | 36.35 | 8.48 | 0.91 | 23.33 | 29.09 | 17.16 | ||
2305.50 | 37,413 Cr | 36.42 | 3.61 | 0.88 | 9.92 | 14.02 | 8.21 | ||
2102.70 | 36,834 Cr | 35.55 | 16.24 | 2.62 | 45.69 | 61.23 | 23.96 | ||
2268.90 | 35,382 Cr | 49.87 | 8.51 | 1.00 | 17.06 | 22.99 | 14.28 | ||
1682.60 | 32,809 Cr | 35.49 | 6.63 | 0.21 | 18.67 | 21.76 | 9.79 | ||
1927.00 | 29,782 Cr | 139.82 | 6.03 | 0.00 | 5.75 | 7.39 | 2.31 | ||
| Median: 7 Co. | — | 2102.70 | 36,834 Cr | 36.35 | 6.63 | 0.88 | 17.06 | 21.76 | 9.79 |
Promoter share sale
Ravi Agrawal Trust, a promoter of Ajanta Pharma Limited, sold 3,450,000 equity shares (2.76% of paid-up equity) in the open market on June 9, 2026; disclosure filed under Reg.29(2) of SEBI (SAST) Regulations.
Promoter share sale
Ravi Agrawal (Trustee, Ravi Agrawal Trust) sold 3,450,000 equity shares (2.76% of paid-up capital) of Ajanta Pharma on June 9, 2026; pre-sale holding was 16,242,904 shares (13.00%) and 5,756,777 shares (4.61%) were encumbered.
Promoter Pledge
Promoter Aayush Agrawal (Trustee, Aayush Agrawal Trust) disclosed creation of a pledge on 2,855,925 Ajanta Pharma shares to secure a new loan; disclosure filed under SEBI (SAST) Reg.31(1)/(2) with BSE/NSE.
Share Pledge
Promoter Aayush Agrawal (Trustee, Aayush Agrawal Trust) has created a pledge over 2,855,925 shares of Ajanta Pharma to secure a new loan, disclosed to stock exchanges under Regulation 31(1)/(2) of SEBI (SAST) Regulations.
Share pledge disclosure
Gabs Investments Pvt. Ltd (promoter) disclosed creation of a pledge on 2,770,000 shares of Ajanta Pharma Limited dated 1 June 2026 to secure a new loan; disclosure signed by director Aayush Agrawal.
